uniQure N.V.
QURE
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.1B
$44.86
▼ -2.96%
P/E
-21.67
Mkt Cap
$3.1B
52-Wk Range
$8.73–$71.50
52-Week Range
$8.73 - $71.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 153.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+60.3% over 3m
Quality
Stable
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying QURE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
JUL 29, 2026
Reported EPS of -$1.22 vs -$0.82 consensus (-48.4% surprise). Revenue of $5.8M vs $5.4M expected (+7.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-48.4%
Revenue trend · last 2Q
—
+11%
Q1 26
Q2 26
$3.6M
$5.8M
Margins · last 2Q
Gross
94.0%
Profit
-1387.8%
Wall Street consensus
9 analysts · 89% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
89%
Hold
11%
Sell
0%
Median Price Target
$80.00
▲ +78.3% vs $44.86
Latest: Wolfe Research · Jul 29, 2026
1 analyst covering
vs Industry
How QURE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.